Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
RESEARCH TOOLSreports
Holding KPTI?
Track your performance easily
KPTI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.62 - $1.95
Previous Close$0.74
Volume453.93K
Average Volume (3M)1.00M
Market Cap
$91.83M
Enterprise Value$37.72M
Total Cash (Recent Filing)$152.12M
Total Debt (Recent Filing)$98.02M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Oct 31, 2024EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding124,683,681
10 Day Avg. Volume478,501
30 Day Avg. Volume1,004,838
Standard Deviation0.20
R-Squared0.00247
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.81
Price to Sales (P/S)0.64
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.26
Enterprise Value/Gross Profit0.27
Enterprise Value/Ebitda-1.50
Forecast
1Y Price Target
$4.40Price Target Upside495.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Karyopharm Therapeutics News
PremiumCompany Announcements
Michael Mason Resigns as CFO of Karyopharm Therapeutics
Bulls Say, Bears Say
Bulls Say
Financial PerformanceKaryopharm reported 2Q24 revenue and EPS of $42.8M and ($0.20), versus estimates of $35.7M and ($0.33), respectively.
Pipeline And Market ExpansionPositive data from any of these studies could dramatically expand the commercial market for Xpovio and move the stock higher.
Revenue GuidanceThe company announced updated total revenue guidance to be in the range of $145M-$160M for FY24, compared to initial guidance of $140M-$160M.
Bears Say
Clinical TrialsTop-line results for the endometrial Phase 3 study have been delayed due to higher-than-expected screen failure rates.
CompetitionEnrollment for the multiple myeloma Phase 3 study has slowed down because of increasing competition from other clinical trials.
Price TargetPrice target has been lowered due to a higher estimated diluted share count.
---
Ownership Overview
14.72% Insiders
13.27% Mutual Funds
30.03% Other Institutional Investors
41.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $0.62 and its highest was $1.95 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Currently, no data Available
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Aug 06, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.298 by $0.098.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -$0.26.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 124,683,680 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.298. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Among the largest hedge funds holding Karyopharm Therapeutics’s share is Woodline Partners LP. It holds Karyopharm Therapeutics’s shares valued at 116K.
---
Karyopharm Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.40 (495.32% Upside)
$4.40 (495.32% Upside)
Blogger Sentiment
Bullish
KPTI Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.15%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
---
KPTI Company Deck
---
KPTI Earnings Call
Q2 2024
0:00 / 0:00
---
KPTI Stock 12 Month Forecast
Average Price Target
$4.40
▲(495.32% Upside)
Technical Analysis
Best Analysts Covering KPTI
1 Year
1 Year Success Rate
1/25 ratings generated profit
1 Year Average Return
-45.85%
reiterated a buy rating 2 months ago
Copying Colleen M. Kusy's trades and holding each position for 1 Year would result in 4.00% of your transactions generating a profit, with an average return of -45.85% per trade.
---